Publicaciones (62) Publicaciones de NATO APTSIAURI

2022

  1. Nanomedicine as a Promising Tool to Overcome Immune Escape in Breast Cancer

    Pharmaceutics, Vol. 14, Núm. 3

  2. The Challenges of HLA Class I Loss in Cancer Immunotherapy: Facts and Hopes

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 28, Núm. 23, pp. 5021-5029

2021

  1. CRC: A Darwinian model of cellular immunoselection

    Foundations of Colorectal Cancer (Elsevier), pp. 529-541

  2. Copy neutral loh affecting the entire chromosome 6 is a frequent mechanism of hla class i alterations in cancer

    Cancers, Vol. 13, Núm. 20

  3. HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy

    Cellular and Molecular Immunology, Vol. 18, Núm. 3, pp. 556-565

  4. Tumor escape phenotype in bladder cancer is associated with loss of HLA class I expression, T-cell exclusion and stromal changes

    International Journal of Molecular Sciences, Vol. 22, Núm. 14

2019

  1. A Combination of Positive Tumor HLA-I and Negative PD-L1 Expression Provides an Immune Rejection Mechanism in Bladder Cancer

    Annals of Surgical Oncology, Vol. 26, Núm. 8, pp. 2631-2639

  2. Cancer immune escape: MHC expression in primary tumours versus metastases

    Immunology, Vol. 158, Núm. 4, pp. 255-266

2018

  1. HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15

    Immunogenetics, Vol. 70, Núm. 10, pp. 647-659

  2. HLA class I loss and PD-L1 expression in lung cancer: Impact on T-cell infiltration and immune escape

    Oncotarget, Vol. 9, Núm. 3, pp. 4120-4133

  3. The transition from HLA-I positive to HLA-I negative primary tumors: the road to escape from T-cell responses

    Current Opinion in Immunology, Vol. 51, pp. 123-132

2017

  1. Rejection versus escape: the tumor MHC dilemma

    Cancer Immunology, Immunotherapy, Vol. 66, Núm. 2, pp. 259-271

  2. The escape of cancer from T cell-mediated immune surveillance: HLA class I loss and tumor tissue architecture

    Vaccines, Vol. 5, Núm. 1

2016

  1. Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance

    Cancer Immunology, Immunotherapy, Vol. 65, Núm. 1, pp. 47-59

  2. Generation of MHC class i diversity in primary tumors and selection of the malignant phenotype

    International Journal of Cancer, Vol. 138, Núm. 2, pp. 271-280

  3. Redefining cancer immunotherapy—optimization, personalization, and new predictive biomarkers: 4th Cancer Immunotherapy and Immunomonitoring (CITIM) meeting, April 27–30, 2015, Ljubljana, Slovenia

    Cancer Immunology, Immunotherapy, Vol. 65, Núm. 7, pp. 875-883

  4. The urgent need to recover MHC class I in cancers for effective immunotherapy

    Current Opinion in Immunology, Vol. 39, pp. 44-51

2014

  1. Adenovirus expressing β2-microglobulin recovers HLA class i expression and antitumor immunity by increasing T-cell recognition

    Cancer Gene Therapy, Vol. 21, Núm. 8, pp. 317-332

  2. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma

    International Journal of Cancer, Vol. 134, Núm. 1, pp. 102-113

2013

  1. MHC class I antigens in malignant cells: Immune escape and response to immunotherapy

    Springer New York, pp. 1-51